
usd feb pm et
summari develop small molecul therapeut treatment wide rang diseas led
cystic fibrosi anti-inflammatori condit
price-to-earnings oper ep
risk assess reflect view vertex
reliant expand cystic fibrosi cf franchis
wider patient sub-group see clear
domin leader market
apr ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
expect sale grow
grow
sale tie cystic
fibrosi cf treatment sale rose
billion revenu
expect cf product revenu grow
year-over-year billion
orkambi sale rose
kalydeco sale rose
manag issu
recent decemb cfo
month resign slightli month
later januari interim cfo
also termin
sudden execut departur concern
regard capit alloc expect
focu extern innov
strategi involv activ licens
collabor like look
opportun expand cystic fibrosi
franchis set technolog tool
earli mid-stag pipelin asset
think share
fair valu see risk share
uncertainti tie execut issu henc
hold rate effort discov tripl
combin regimen treat cf could
cf popul
estim patient doubl
cf patient current estim
elig treatment
sever on-going phase trial tripl
combin regimen could file new
drug applic nda regimen
exposur therapeut area includ
pain sickl cell diseas beta thalassemia
pipelin could make attract
risk opinion target price includ
failur expand cf franchis
greater-than-expect discount orkambi
kalydeco payer pushback pipelin
failur poor new product
target base
slightli averag
ep
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
corpor overview biotechnolog compani focus discoveri
develop breakthrough small molecul drug seriou diseas compani product pipelin
focus viral diseas cystic fibrosi inflamm autoimmun diseas epilepsi
partnership cystic fibrosi foundat studi novel small molecul
treatment cystic fibrosi cf rare respiratori diseas afflict roughli patient world-wide
lead candid oral dose kalydeco approv januari treat adult cf
patient rare mutat repres around total patient popul
drug approv europ juli
orkambi lumacaftor combin ivacaftor approv unit state food drug
administr fda european commiss treatment patient cf
year age older two copi homozyg mutat cf
transmembran conduct regul cftr gene compani complet first two phase
clinic trial evalu lumacaftor combin ivacaftor treatment patient cf six
year age homozyg mutat cftr gene
kalydeco ivacaftor orally-administ cftr potenti approv unit state
european union australia canada treatment certain patient cf specif
mutat cftr gene unit state kalydeco approv treatment patient
cf two year age older one mutat cftr gene includ
european union
kalydeco approv treatment patient cf two year age older one
follow mutat cftr gene
year age older mutat cftr gene
symdeko tezacaftor/ivacaftor ivacaftor approv fda februari therapi
cystic fibrosi cf patient carri two copi mutat cftr gene gene
defect cf one mutat respond tezacaftor/ivacaftor symdeko third
product approv cf patient
pipelin compani multipl develop program field cf includ
tripl combin regimen current phase clinic trial
beyond cf pain program includ select inhibitor repres first
proof concept inhibit treatment acut pain chronic inflammatori pain
phase ii result third type pain neuropath pain expect earli howev
stop develop base pharmacokinet toler find
also partner crispr advanc first gene edit treatment
sickl cell diseas beta-thalassemia use technolog beta-thalassemia
obtain approv clinic trial applic cta earli
obtain cta approv canada expect initi first studi
beta-thalassemia late sickl cell diseas obtain cta approv canada
howev continu work fda address agenc question regard ind
submit earli
impact major develop juli receiv fda approv orkambi treat
underli caus cystic fibrosi approv signific mileston event
gener billion dollar sale enabl becom clear market leader treatment
cf septemb orkambi approv treat children two copi
mutat approxim children age elig treatment kalydeco
approv januari treat adult cf patient rare mutat
repres around total patient popul drug approv europ juli
end sale distribut hepat drug incivek follow success gilead
scienc hepat drug sovaldi incivek approv sale billion
howev sale start declin earli physician patient await approv
sovaldi much better efficaci rate
financi trend sale consist almost exclus cf drug rose million
billion repres three-year compound annual growth rate compound-annual-growth-rate
adjust earn loss per share develop cost exceed revenu becam
profit achiev ep ep doubl first
turn profit adjust ep driven success hepat drug incivek
howev end incivek sale due success compet product
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
signific chang near futur
anoth sourc price pressur drug
manufactur pharmaci benefit
manag pbm health insur
exert influenc drug prescript
price pressur like increas
major pbm merg soon
merg major insur cvs-aet
merger acquisit climat
appear warm matur
biopharmaceut firm made
mark blockbust drug look
off-set lost revenu expir patent
promis late-stag pipelin addit
biotechnolog compani low debt
level attract valuat --
reason favor environ
biolog price competit
innov act bpcia grant
exclus period brand biolog
maker sinc brand biolog
manufactur aggress use patent
law commerci leverag delay
commerci biosimilar
maintain market domin
longer result expect biosimilar
continu advanc slowli next
 biotech index declin
vs declin
posit fundament outlook
defens sub-industri expect
see commerci develop
mani new innov therapi declin
preval patent expir
start favor announc
mega merger agreement celgen
celg bristol-mey squibb
compani trade
signific discount market
think remedi robust pipelin
drug brought market fda approv
novel drug increas
shatter previou record sinc
novel approv set
rapid growth novel drug
gener competitor expect see robust
sale growth biopharmaceut firm
think mani drug either
newly-approv late-stag clinic trial
consider commerci prospect
repres major advanc therapi
diseas cystic fibrosi hepat
multipl sclerosi cancer exampl
fda approv first gene-therapi
drug genet alter patient immun
cell first-ev rna-interference-bas
think growth biotechnolog stock
slightli limit high drug price
 heighten scrutini
 polit apparatu last
year despit talk lower drug
price seen particularli sever
measur taken legisl regulatori
bodi lower drug price
democrat took hous
repres novemb midterm
elect appear motiv
address drug price still think
suffici impetu affect
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain hold opinion share
maintain target slightli
averag ep ep vs
higher estim maintain ep estim
initi ep revenu increas million
driven us launch symdeko sale includ million
symdeko us regard capit alloc expect
focu extern innov strategi involv activ
licens collabor like look opportun
expand cystic fibrosi franchis set technolog tool
earli mid-stag pipelin asset exampl research
develop therapi sickl cell diseas pain patient small fiber
neuropathi beta-thalessemia provid detail
departur two cfo past sever month continu view
uncertainti signific risk /kevin huang cfa
et cfra keep buy opinion share vertex
pharmaceut incorpor keep
target above-p ratio due view robust growth
prospect base ep estim ep vs
ahead view sale cystic fibrosi cf product rose
aid launch symdeko solid growth kalydeco
orkambi symdeko receiv fda approv treat cf patient age
two copi mutat least one mutat
respons tezacraftor/ivacaftor expect symdeko receiv eu
approv believ cf patient world-wide elig
product half patient product see
signific growth potenti pend approv cf product patient
age fda action date august kalydeco
patient age august fda action date orkambi
et cfra reiter buy opinion share vertex
pharmaceut incorpor rais
target above-p ratio robust growth prospect
rais ep estim set ep
vs ahead view cystic fibrosi cf product
sale grew orkambi kalydeco
tezacaftor/ivacaftor combin fda action date februari
expect approv select advanc phase
develop part two differ tripl combin regimen
think could treat cf patient /jeffrey loo cfa
et cfra lower opinion share hold
buy maintain target price
lower opinion share hold see increas
risk near-term share price perform what-appears-to-b c-suit
issu yesterday termin interim cfo ian smith also
compani person behavior violat vertex code
conduct valu last month then-cfo thoma graney
announc immedi resign cfo view departur two cfo
within less two month red flag addit delay
announc earn call year consist
announc first week januari past four year concern
event may indic issu compani
could innocu explan impact compani valu
see increas near-term risk due uncertainti /kevin huang cfa
et cfra reiter buy opinion share vertex
pharmaceut incorpor maintain
target slightli three-year averag
ep estim ep vs
higher estim rais ep
lower ep futur increas tax rate
sale increas million launch symdeko
symdeko saw rapid uptak across elig patient
sale million cf revenu also receiv
approv kalydeco orkambi young children continu work
develop pipelin branch cf treatment
area includ pain sickl cell diseas beta thalassemia
octob crispr announc fda lift
clinic hold investig new drug applic treatment
sickl cell diseas compani plan initi phase studi
pharmaceut incorpor rais
target price line peer ratio base
forward ep estim anticip continu robust sale
growth obtain addit price reimburs agreement
countri cystic fibrosi cf drug also believ tripl
combin regimen treat cf could significantli expand market
opportun trial current phase success meet
primari end point think could potenti file nda
tripl combin regimen also two pend fda action
date august expand cf treatment younger patient ep
vs ahead estim rais ep
estim ep estim sale rose
driven success launch symdeko addit
countri agre price reimburs cf drug /jeffrey
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
